Bimodal anti-glioma mechanisms of cilengitide demonstrated by novel invasive glioma models

Neuropathology

Volumn 33, Issue 2, 2013, Pages 162-174

  Onishi, Manabu ^a   Ichikawa, Tomotsugu ^a   Kurozumi, Kazuhiko ^a   Fujii, Kentaro ^a   Yoshida, Koichi ^a   Inoue, Satoshi ^a   Michiue, Hiroyuki ^a   Chiocca, E Antonio ^b   Kaur, Balveen ^c   Date, Isao ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b Brigham andWomen's   (Japan)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Angiogenesis; Animal model; Glioma; Integrin; Invasion

Indexed keywords

CILENGITIDE; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN TUMOR; CELL CULTURE; CELL INFILTRATION; CELL INVASION; CONTROLLED STUDY; ENDOTHELIUM CELL; EXPERIMENTAL THERAPY; GLIOMA; GLIOMA CELL; IMMUNOHISTOCHEMISTRY; NONHUMAN; NUDE RAT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COCULTURE TECHNIQUES; DISEASE MODELS, ANIMAL; DOGS; GLIOMA; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; RATS; RATS, NUDE; SNAKE VENOMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84875796771     PISSN: 09196544     EISSN: 14401789     Source Type: Journal    
DOI: 10.1111/j.1440-1789.2012.01344.x     Document Type: Article

References (39)

1. Stupp R, Mason WP, van den Bent MJ etal. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
2. Chatterjee S, Matsumura A, Schradermeier J, Gillespie GY. Human malignant glioma therapy using anti-alpha(v)beta3 integrin agents. J Neurooncol 2000; 46: 135-144.
3. Tate MC, Aghi MK. Biology of angiogenesis and invasion in glioma. Neurotherapeutics 2009; 6: 447-457.
4. Onishi M, Ichikawa T, Kurozumi K, Date I. Angiogenesis and invasion in glioma. Brain Tumor Pathol 2011; 28: 13-24.
5. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2: 727-739.
6. Vredenburgh JJ, Desjardins A, Herndon JE, 2nd etal. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007; 13: 1253-1259.
7. Vredenburgh JJ, Desjardins A, Herndon JE, 2nd etal. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25: 4722-4729.
8. de Groot JF, Fuller G, Kumar AJ etal. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol 2010; 12: 233-242.
9. Reardon DA, Nabors LB, Stupp R, Mikkelsen T. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs 2008; 17: 1225-1235.
10. Varner JA, Cheresh DA. Integrins and cancer. Curr Opin Cell Biol 1996; 8: 724-730.
11. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct alpha v integrins. Science 1995; 270: 1500-1502.
12. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994; 264: 569-571.
13. Brooks PC, Montgomery AM, Rosenfeld M etal. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79: 1157-1164.
14. Hodivala-Dilke KM, Reynolds AR, Reynolds LE. Integrins in angiogenesis: multitalented molecules in a balancing act. Cell Tissue Res 2003; 314: 131-144.
15. Leavesley DI, Ferguson GD, Wayner EA, Cheresh DA. Requirement of the integrin beta 3 subunit for carcinoma cell spreading or migration on vitronectin and fibrinogen. J Cell Biol 1992; 117: 1101-1107.
16. MacDonald TJ, Taga T, Shimada H etal. Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery 2001; 48: 151-157.
17. Oliveira-Ferrer L, Hauschild J, Fiedler W etal. Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway. J Exp Clin Cancer Res 2008; 27: 86-99.
18. Alghisi GC, Ponsonnet L, Ruegg C. The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells. PLoS ONE 2009; 4: e4449.
19. Tucker GC. Alpha v integrin inhibitors and cancer therapy. Curr Opin Investig Drugs 2003; 4: 722-731.
20. Inoue S, Ichikawa T, Kurozumi K etal. Novel animal glioma models that separately exhibit two different invasive and angiogenic phenotypes of human glioblastomas. World Neurosurg 2011. doi: 10.1016/j.wneu.2011.09.005.
21. Hampl JA, Camp SM, Mydlarz WK etal. Potentiated gene delivery to tumors using herpes simplex virus/Epstein-Barr virus/RV tribrid amplicon vectors. Hum Gene Ther 2003; 14: 611-626.
22. Bishop ET, Bell GT, Bloor S, Broom IJ, Hendry NF, Wheatley DN. An in vitro model of angiogenesis: basic features. Angiogenesis 1999; 3: 335-344.
23. Igarashi T, Miyake K, Kato K etal. Lentivirus-mediated expression of angiostatin efficiently inhibits neovascularization in a murine proliferative retinopathy model. Gene Ther 2003; 10: 219-226.
24. Bouchard V, Demers MJ, Thibodeau S etal. Fak/Src signaling in human intestinal epithelial cell survival and anoikis: differentiation state-specific uncoupling with the PI3-K/Akt-1 and MEK/Erk pathways. J Cell Physiol 2007; 212: 717-728.
25. Cifarelli CP, Titus B, Yeoh HK. Cadherin-dependent adhesion of human U373MG glioblastoma cells promotes neurite outgrowth and increases migratory capacity. Laboratory investigation. J Neurosurg 2011; 114: 663-669.
26. Izumoto S, Ohnishi T, Arita N, Hiraga S, Taki T, Hayakawa T. Gene expression of neural cell adhesion molecule L1 in malignant gliomas and biological significance of L1 in glioma invasion. Cancer Res 1996; 56: 1440-1444.
27. Yamada S, Bu XY, Khankaldyyan V, Gonzales-Gomez I, McComb JG, Laug WE. Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice. Neurosurgery 2006; 59: 1304-1312; discussion 1312.
28. Norden AD, Young GS, Setayesh K etal. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008; 70: 779-787.
29. Kunkel P, Ulbricht U, Bohlen P etal. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 2001; 61: 6624-6628.
30. Rubenstein JL, Kim J, Ozawa T etal. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000; 2: 306-314.
31. Tuettenberg J, Friedel C, Vajkoczy P. Angiogenesis in malignant glioma - a target for antitumor therapy? Crit Rev Oncol Hematol 2006; 59: 181-193.
32. Platten M, Wick W, Wild-Bode C, Aulwurm S, Dichgans J, Weller M. Transforming growth factors beta(1) (TGF-beta(1)) and TGF-beta(2) promote glioma cell migration via Up-regulation of alpha(V)beta(3) integrin expression. Biochem Biophys Res Commun 2000; 268: 607-611.
33. Gilbert MR, Kuhn J, Lamborn KR etal. Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. J Neurooncol 2012; 106: 147-153.
34. Reardon DA, Fink KL, Mikkelsen T etal. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 2008; 26: 5610-5617.
35. Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S, DeNardo GL. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res 2002; 62: 4263-4272.
36. Abdollahi A, Griggs DW, Zieher H etal. Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res 2005; 11: 6270-6279.
37. Tentori L, Dorio AS, Muzi A etal. The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma. Oncol Rep 2008; 19: 1039-1043.
38. Mikkelsen T, Brodie C, Finniss S etal. Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. Int J Cancer 2009; 124: 2719-2727.
39. Kurozumi K, Hardcastle J, Thakur R etal. Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst 2007; 99: 1768-1781.